A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.
OBJECTIVE
To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease.


METHODS
Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain.


RESULTS
All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate.


CONCLUSIONS
Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.
Huilgol
N G
NG
Division of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai, India. nagrajh@vsnl.net
Nair
C K K
CK
Merhotra
P
P
Kagiya
V T
VT
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000532:radiotherapy*; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D017619:Hemibody Irradiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024505:Tocopherols / Q000009:adverse effects / Q000627:therapeutic use
D005960:Glucosides; D011837:Radiation-Protective Agents; C460320:tocopherol monoglucoside; D024505:Tocopherols